by Portfolio Grader | September 26, 2012 6:33 pm
Six Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Incyte Corp. (NASDAQ:INCY) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. In Portfolio Grader’s specific subcategories of Earnings Momentum, Earnings Revisions, and Sales Growth, INCY also gets A’s. For more information, get Portfolio Grader’s complete analysis of INCY stock.
This week, Gilead Sciences (NASDAQ:GILD) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. Shares of GILD have increased 17.5% over the past month, better than the 1.6% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of GILD stock.
EXACT Sciences‘s (NASDAQ:EXAS) ratings are looking better this week, moving up to a B from last week’s C. Exact Sciences is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. Wall Street has pushed the stock higher by 12.8% over the past month. For more information, get Portfolio Grader’s complete analysis of EXAS stock.
Vical Inc. (NASDAQ:VICL) improves from a C to a B rating this week. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 29% over the past month. For more information, get Portfolio Grader’s complete analysis of VICL stock.
Maxygen (NASDAQ:MAXY) boosts its rating from a C to a B this week. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock has a trailing PE Ratio of 3.5. For more information, get Portfolio Grader’s complete analysis of MAXY stock.
BioMimetic Therapeutics (NASDAQ:BMTI) earns a B this week, jumping up from last week’s grade of C. BioMimetic Therapeutics engages in the development and commercialization of regenerative protein therapeutic products primarily used for bone and tissue regeneration, repair and healing of musculoskeletal injuries, and conditions affecting bones, tendons, ligaments, and cartilage. Investors have pushed the stock price up 22.8% over the past month. For more information, get Portfolio Grader’s complete analysis of BMTI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/09/6-biotechnology-stocks-to-buy-now-incy-gild-exas/
Short URL: http://invstplc.com/1nB12OG
Copyright ©2014 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.